Greenbrook TMS Announces Appointment of Robert Higgins to the Board

Rhea-AI Summary

Greenbrook TMS Inc. (NASDAQ: GBNH) has appointed Robert Higgins to its board of directors, expanding the board to nine members. Higgins, co-founder of Masters Special Situations, brings extensive experience in healthcare investment and legal expertise. His past roles include Vice President at Arosa+LivHOME and various positions at Goldman Sachs and Sidley Austin LLP. Greenbrook operates 129 treatment centers, specializing in Transcranial Magnetic Stimulation (TMS) therapy, having delivered over 620,000 treatments to more than 17,000 patients.

Positive

• Robert Higgins' appointment may provide valuable insights and new perspectives to the board.
• Higgins' extensive background in healthcare investment could enhance the company's strategic direction.

Negative

• Concerns may arise regarding board continuity and experience gaps due to recent changes.

Greenbrook TMS Inc. (TSX: GTMS, NASDAQ: GBNH) (“Greenbrook” or the “Company”) is pleased to announce the appointment of Robert Higgins to the board of directors of the Company (the “Board”), effective immediately. The appointment of Mr. Higgins increases the size of the Board to nine members.

Mr. Higgins is currently Managing Director, Investment Professional & General Counsel of Masters Special Situations, LLC (“MSS”), a healthcare focused growth equity firm which he co-founded in 2020. Prior to co-founding MSS, Mr. Higgins was Vice President, Business Development & General Counsel of Arosa+LivHOME, a Bain Capital Double Impact Portfolio Company, and a premier national provider of integrated care management and caregiving services. Prior to his time with Arosa+LivHOME, Mr. Higgins held a variety of both investment and legal roles, including as an investment adviser in the Investment Management Division of Goldman Sachs and as a corporate attorney at Sidley Austin LLP. Mr. Higgins holds a bachelor’s degree from Duke University and a master’s degree from the London School of Economics. He earned his J.D., cum laude, from Washington University in St. Louis School of Law and is a member of the New York State Bar.

About Greenbrook TMS Inc.

Operating through 129 Company-operated treatment centers, Greenbrook is a leading provider of Transcranial Magnetic Stimulation (“TMS”) therapy, an FDA-cleared, non-invasive therapy for the treatment of Major Depressive Disorder and other mental health disorders, in the United States. TMS therapy provides local electromagnetic stimulation to specific brain regions known to be directly associated with mood regulation. Greenbrook has provided more than 620,000 TMS treatments to over 17,000 patients struggling with depression.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210803005270/en/

FAQ

Who is Robert Higgins, and what experience does he bring to Greenbrook TMS?

Robert Higgins is the newly appointed board member of Greenbrook TMS, with experience as Managing Director at Masters Special Situations and roles at Arosa+LivHOME and Goldman Sachs.

What is the significance of increasing the board size to nine members?

Increasing the board size to nine members may enhance decision-making and diversity of thought within Greenbrook TMS.

How many treatment centers does Greenbrook TMS operate?

Greenbrook TMS operates 129 treatment centers across the United States.

What is Transcranial Magnetic Stimulation (TMS) therapy?

TMS therapy is an FDA-cleared, non-invasive treatment for Major Depressive Disorder and other mental health disorders, utilizing electromagnetic stimulation to target mood-regulating brain regions.

How many TMS treatments has Greenbrook provided?

Greenbrook has delivered over 620,000 TMS treatments to more than 17,000 patients.